Cargando…
For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs
The price of cancer drugs has skyrocketed, yet it is not clear whether their value is commensurate with their price. More cancer drugs are approved under expedited review, which considers less rigorous clinical evidence, yet only 20% of them show an overall survival gain in the confirmatory trial. M...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998346/ https://www.ncbi.nlm.nih.gov/pubmed/35409887 http://dx.doi.org/10.3390/ijerph19074204 |